FDA expands KASA review program to drug substances
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyGenericsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory writing/documentationRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyGenericsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory writing/documentation